79974-35-9

Usage

Uses

Used in Pharmaceutical Industry:
(4E)-4-imino-1-pentofuranosyl-1,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-amine is used as a potential pharmaceutical agent for its possible interaction with biological molecules and processes in the body. Its complex structure and the presence of functional groups such as the imino and amine groups may contribute to its medicinal properties, making it a candidate for further research and development in the pharmaceutical field.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (4E)-4-imino-1-pentofuranosyl-1,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-amine serves as a subject for investigation due to its unique structure and potential biological activity. Researchers may explore its interactions with various biological targets, which could lead to the discovery of new therapeutic agents or a better understanding of biological processes.

Upstream product

• 3258-05-7 4-amino-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine 

Downstream Products

• 79974-42-8 7-(β-D-ribofuranosyl)pyrazolo<4,3-e>-1,2,4-triazolo<2,3-c>-1,2,3-triazine 
• 79974-37-1 7-(β-D-ribofuranosyl)pyrazolo<4,3-e>-1,2,4-triazolo<1,5-c>pyrimidine 
• 79974-41-7 5-amino-1-(β-D-ribofuranosyl)-4-(1,2,4-triazol-3-yl)pyrazole 

Relevant academic research and scientific papers

Synthesis of Certain Fluorescent Tricyclic Nucleosides Derived from PyrazoloPyrimidine Nucleosides

The synthesis of certain tricyclic nucleosides with a dihydroimidazole, imidazole, triazole, or tetrazole ring fused to the pyrazolopyrimidine ring system in an angular position (C-4 and N-5) has been accomplished.The 4-aziridinyl derivative (2) was prepared by a nucleophilic displacement of the chlorine atom of 4-chloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)pyrazolopyrimidine (1) with ethylenimine.The nucleoside (2) was then treated with sodium iodide to furnish 7-(β-D-ribofuranosyl)-2,3-dihydroimidazopyrazolopyrimidine (3).The reaction of (1) with lithium azide gave 7-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)pyrazolotetrazolopyrimidine (5) and cyclization of 4-amino-1-(β-D-ribofuranosyl)pyrazolopyrimidine with chloroacetaldehyde provided the tricyclic nucleoside 7-(β-D-ribofuranosyl)imidazopyrazolopyrimidine (7). 2,4-Dinitrophenoxamine was treated with 4-amino-1-(β-D-ribofuranosyl)pyrazolopyrimidine (6) to give an intermediate (8) which on cyclization with diethoxymethyl acetate gave 7-(2,3-O-methoxymethylene-β-D-ribofuranosyl)pyrazolo-1,2,4-triazolopyrimidine (9).Acid-catalysed deblocking of (9) provided the desired tricyclic nucleoside (10).The reaction of trimethyl orthoformate with 4-hydrazino-1-(β-D-ribofuranosyl)pyrazolopyrimidine under different experimental conditions resulted in the formation of a mixture of diastereoisomers due to the 2',3'-O-methoxymethylene group.Treatment of (10) with alkali gave a ring-opened intermediate which on treatment with sodium nitrite and acetic acid cyclized to give an aza-derivative (16) of (10).